Here are Tuesday’s biggest calls on Wall Street:
Evercore ISI reiterates Tesla as in line
Evercore says the stock is likely to “see-saw” for the foreseeable future.
“For TSLA, who doesn’t guide, the stock is likely a short-term seesaw between lackluster legacy (~$100 of value; ~40c EPS Q4/Q1) vs headline/thematic focus on Austin ‘driver out.’”
Bank of America reiterates Nvidia as buy
Bank of America says Nvidia is still a top AI pick following the company’s presentation at the Consumer Electronics Show on Monday.
“We continue to highlight NVDA’s continued dominance in AI compute, networking, system, and ecosystem, trading at just ~19x CY27E PE or in-line with broader SPX despite its superior >35% EPS CAGR and >40% FCF.”
JPMorgan initiates Parker-Hannifin at overweight
JPMorgan says the stock is a “mega cap compounder with industrial strength.”
“Lastly, what it lacks in market tailwinds, it has made up for with smart capital allocation, with Parker probably one of the few remaining companies that could be considered a premium ‘compounder.’”
Jefferies upgrades Brunswick to buy from hold
Jefferies says the boat company is evolving.
“BC has evolved beyond the traditional boat OEM [original equipment manufacturer]. Its pivot toward higher-margin segments (Propulsion – 37% of sales; Parts & Accessories – 35% of sales) and recurring revenue streams (Parts & Accessories + Freedom Boat Club) has structurally improved the biz.”
Morgan Stanley initiates Belite Bio at overweight
Morgan Stanley says the biotech company has a first mover advantage.
“We initiate coverage of BLTE with an Overweight rating and a $191 price target.”
Evercore ISI upgrades SLB to outperform from in line
Evercore says shares of the oilfield services company have plenty more room to run.
“The outlook at SLB is much clearer than it has been in 2+ years.”
UBS upgrades Fifth Third to buy from neutral
UBS calls the regional bank best-in-class.
“We see FITB charting a similar course of achieving both best-in-class profitability and best-in-class growth, with opportunities augmented by the CMA deal.”
Morgan Stanley initiates Bridge Bio at overweight
Morgan Stanley says the biotech company has robust growth potential.
“BridgeBio Pharma is positioned as a leading rare/genetic disease company, with Attruby and a diversified late-stage pipeline driving strong growth potential.”
UBS upgrades Trex to buy from neutral
UBS says the “growth algo” is intact for the wood decking company.
“We U/G TREX from NTRL to Buy and raise our ’27–’29 rev and adj EBITDA.”
UBS initiates China Yuchai at buy
UBS says the China diesel engine company is best positioned.
“Yuchai is the second largest diesel engine OEM in China with a 14% market share. It has emerged as a leader in the high horsepower engine sector in China with a market share of more than 40% in 2025, by our estimate.”
Deutsche Bank upgrades Shake Shack to buy from hold
Deutsche says shares are compelling at current levels.
“We are also upgrading SHAK to Buy given what we see as a compelling catalyst path in 1H26, still strong growth outlook and near trough valuation.”
UBS upgrades Brinker to buy from neutral
UBS says the owner of brands like Chili’s has robust same-store sales momentum.
“We upgrade EAT to Buy (from Neutral) and raise our price target to $175 from $144 based on ~8.5x (from ~7.5x) our NTM EBITDA, reflecting expectations that leading sss momentum will continue while earnings upside exists given sales leverage.”
BTIG upgrades Core Scientific to buy from neutral
BTIG says the company has a “dominant” data center portfolio.
“With the dust settled following CORZ shareholder rejection of its merger with CoreWeave, we upgrade to Buy from Neutral.”
RBC upgrades Diageo to outperform from sector perform
RBC likes the beverage company’s management.
“If Diageo is to restore its fortunes, it needs to revitalise its mainstream business and accept that the luxury portfolio is an important, but limited, part of the whole. Mainstream is where incoming CEO Sir Dave Lewis has spent his career.”
Baird downgrades Wells Fargo to underperform from neutral
The firm says sell the stock “into further strength.”
“Downgrading WFC to Underperform. … However, with the stock trading at ~2.2x TBV, the ROTCE target seems more than priced in at these prices, and we would recommend selling into further strength.”
Bank of America reiterates Apple as buy
Bank of America says it’s sticking with its buy rating following checks showing Apple’s App Store revenue growing year over year.
“Maintain Buy on strong capital returns, eventual leader at AI at the edge & optionality from new products/markets.”
Evercore ISI initiates UnitedHealth at outperform
Evercore says the healthcare company has earnings power.
“We are initiating on UnitedHealth Group with an Outperform rating and target price of $400 (~20% upside).”
JPMorgan initiates Wealthfront at overweight
JPMorgan says the wealth management platform is attractive.
“We are initiating coverage of Wealthfront with an Overweight rating.”
Wells Fargo upgrades Landstar Systems to overweight from equal weight
Wells says the trucking company is best positioned.
“We believe continued spot rate improvement is possible as TL [truckload] capacity is rationalized and demand is consistent/improves. Landstar is highly exposed to spot, and we see upside to estimates beyond 1Q.”
Raymond James upgrades Stryker to outperform from market perform
Raymond James says shares are attractive.
“SYK has been one of the highest quality compounders for the last five years, but the forward multiple compressed in 2025, as estimates trended higher. This does not make full sense to us, and we believe the current valuation represents an attractive entry point.”
Bank of America upgrades Brookdale Living to buy from underperform
The firm says industry dynamics are improving for the senior living company.
“We double upgrade Brookdale (BKD) to Buy from Underperform as we believe its improved portfolio and positive FCF position it better to benefit from the favorable industry dynamics.”
Citigroup upgrades Ball Corp to buy from neutral
Citi says it’s bullish on the packaging company.
“We see a potentially sizable gap in ’26/’27 vol growth as BALL adds new capacity and glass is overweight challenged categories.”
Truist initiates Palantir at buy
Truist says the company has a “leading software platform.”
“We acknowledge the significant valuation premium PLTR commands, but continue to view it as a Buy given its significant opportunity to drive GenAI adoption for governments & enterprises.”
Wells Fargo downgrades D.R. Horton to equal weight from overweight
Wells says things look “tough” for the homebuilder right now.
“DHI is by far one of the best managed production builders out there, w/ unmatched scale & an enviable manufacturing model/attractive land strategy. But against persistent peer discounting & DHI’s own investments in spec inventories it’s just too tough to recommend an entry level builder, however well run. Thus, we move DHI to EW as things could be tough before improving.”
Evercore ISI upgrades Fortrea to outperform from in line
Evercore says the clinical pharmacology company is well positioned.
“We are upgrading shares of FTRE today with a new price target of $25. Our upgrade is based on the accelerating biopharma cycle and improved accountability and performance within Fortrea driving higher revenue and margins vs. consensus estimates, as well as the benefits of deleveraging.”
Stephens upgrades Saia to overweight from equal weight
Stephens says the transportation company is a self-help story.
“We are upgrading SAIA to OW (from EW) as we believe it has ample self-help with its new network that will drive earnings growth in the coming years.”
